January 6, 2025 - Pharma Strategies | Zimbabwe | Zambia & beyond!

Phone: +263 (242) 741 308/9

Home
About Us
Our Work
News
Media
Links
Privacy Policy
Contact
Search
Menu Menu

Alcon 11/12/2025 : Alcon’s Third Quarter 2025 Earnings Conference Call

January 6, 2025/by Alcon Events

http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png 0 0 Alcon Events http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png Alcon Events2025-01-06 23:35:192025-01-06 23:35:1911/12/2025 : Alcon’s Third Quarter 2025 Earnings Conference Call

NEWS SOURCES

Alcon
Novartis News
Sandoz News

TAGS

Alcon Antidiabetics Blood Pressure Cancer Galvus Galvus Met Malaria Novartis Oral Antidiabetics Osteoarthritis Read more about A cancer patient gets a new lease on life Read more about A partnership against epilepsy Read more about A personal journey full circle, from curiosity about life on Earth to transformative therapies at Novartis Read more about Belonging here: How Novartis helped me come out as a transgender woman Read more about FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade Read more about From black holes to AI driven drug discovery – collaboration wins the day Read more about Giving voice to people with a misunderstood disease Read more about How I found my true purpose at Novartis Read more about Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease Read more about Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions Read more about Mentoring matters: how we grow together at Novartis Read more about New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients Read more about Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies Read more about Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio Read more about Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2 Read more about Novartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration Read more about Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline Read more about Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben Read more about Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA Read more about Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2 Read more about Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G) Read more about Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer Read more about Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash Read more about Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial Read more about Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria Read more about Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH Read more about Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile Read more about Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML Read more about Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH Read more about Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day Read more about Official partner of the Eurovision Song Contest 2025 Read more about Violence against innocent people runs counter to our work to improve human health Read more about Water project revives rural community in India Rheumatoid Arthritis Sandoz

MENU

Home
About Us
Our Work
News
Media
Links
Privacy Policy
Contact

Calendar

January 2025
M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

« Dec Feb »

Follow us on Facebook

ADDRESS – ZIMBABWE

Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe

ADDRESS – ZAMBIA

Plot 43504
Apex Chalala
Off Kasama Road
Lusaka Zambia

News

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle painAugust 30, 2025 - 5:04 pm

© Copyright 2015-2025 - PharmaStrategies Site by Gracia Studios

Privacy Policy